Endocrine Abstracts

Ischaemic stroke is a debilitating process. Diabetes is a highly prevalent comorbidity and is associated with poorer stroke outcomes. Glucose monitoring is recommended for all patients with acute stroke. GLP 1-agonists (GLP1-RA) and SGLT 2 inhibitors (SGLT2i) medications are associated with reduced major adverse cardiovascular events post ischaemic stroke. We analysed ischemic stroke admissions to Tipperary University Hospital over a one year period by performing a retrospective chart review. We extracted data on stroke management, general and diabetic demographics, HbA1c levels, post-stroke outcomes, medication and discharge information. 86 ischemic strokes were analysed. 16 (19%) patients had pre-existing diabetes. Two were newly diagnosed with diabetes during admission. 72 (83%) patients had their stroke treated medically, eight were thrombolysed with five undergoing thrombectomy. No significant difference in treatment was observed among those with diabetes. HbA1c levels were checked in 95% with a mean HbA1c of 61.3 mmol/l/mol among those with diabetes. Blood glucose monitoring was performed on all patients. 16 patients had a poor outcome, defined as death, nursing home admission, or disability. Only one of the 16 had diabetes. Four patients were discharged on GLP 1-RA and 14 on SGLT2i. Prevalence of diabetes of 19% in our stroke cohort is lower than described in previous studies. Treatments and outcomes were similar to those without diabetes. High rates of glucose monitoring and HbA1c testing were achieved. Glycaemic control in the diabetes cohort was reasonable, which may have contributed to the similar outcomes observed. SGLT2i use was high but GLP 1-RA use was low.